Gandhi Medicos

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

Dolutegravir is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 12 years of age and older and weighing at least 88 pounds (40 kilograms). Dolutegravir is always used in combination with other HIV medicines.

Dolutegravir belongs to a class (group) of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integrase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body. HIV medicines can’t cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission

What side effects can dolutegravir cause?

Dolutegravir may cause side effects. Most side effects from dolutegravir are manageable, but a few can be serious. Serious side effects of dolutegravir include allergic reactions and liver problems. (See the WARNING above.)Other possible side effects of dolutegravir include:

Changes in liver test results. People with a history of HBV or HCV may have an increased risk of developing new or worsening changes in certain liver test results during treatment with dolutegravir.
Changes in body fat (including gain or loss of fat).

Immune reconstitution inflammatory syndrome (IRIS), a condition that sometimes occurs when the immune system begins to recover after treatment with an HIV medicine. As the immune system gets stronger, it may have an increased response to a previously hidden infection.
Trouble sleeping.
Tiredness.
Headache.
Tell your health care provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of dolutegravir. To learn more about possible side effects of dolutegravir, read the drug label or package insert or talk to your health care provider or pharmacist.The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to dolutegravir.

30 Tab

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.

• Imatikast (Imatinib 400 mg), the indigenous drug, is used for patients with different types of blood cancer caused due to irregular growth of white blood cells (WBCs). Imatikast 400-800 mg (Imatinib) hinders the growth of these abnormal cells and induces the mechanism of self-destruction (apoptosis) in them.